Supply Chain
-
Biosimilars, Caught my eye, Drug Prices, Drug shortages, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Obesity, Supply Chain, ValueCaught my eye — 4/11/25
Read more: Caught my eye — 4/11/25Some days I sit down the pottery wheel and I pull 4 bowls or vases in a row that are fantastic. Other days (like, oh, this Sunday and Wednesday) it all collapses. Here is hoping that all of us get better at staying centered and not collapsing. I’d Prefer Not. The 2026 Medicare Advantage and…
-
Caught my eye — 2/28/25
Read more: Caught my eye — 2/28/25Tariffic. This week Eli Lilly announced they were investing at least $27 billion in US manufacturing, which is pretty cool. Was it to buy favor with the new Administration? It certainly does not hurt. I get the allure of manufacturing in the United States. If a country wanted to hurt us, they could stop sending…
Latest news
- Catch as Catch Can
- Make IRA Better
- Spring break broke me
- Caught my eye — 4/11/25
- Caught my eye — 4/4/25
Categories
- 340B (34)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (21)
- Caught my eye (63)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (11)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (32)
- Drug shortages (9)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (10)
- Importation (2)
- Inflation Reduction Act (48)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (16)
- Medicare Negotiation (50)
- Medicare Part D (46)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (8)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (29)
- Reference Pricing (6)
- State-based Reform (15)
- Supply Chain (2)
- Uncategorized (6)
- Utilization Management (1)
- Vaccines (4)
- Value (13)